Meeting
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Authors
Aman Chauhan
University of Kentucky Department of Medicine, Lexington, KY;
Aman Chauhan , Jill Kolesar , Donglin Yan , Daneng Li , Aman Khurana , William Edgar Carson III, Susanne M. Arnold , Steven Gore , Larry Rubinstein , Elise C. Kohn , Percy Ivy , Ying Xiao , Yuni Dewaraja , Heloisa P. Soares , Jan Hendrik Beumer , Bhavana Konda , Vineeth Sukrithan , Lowell Brian Anthony
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
04750954
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS658)
DOI
10.1200/JCO.2023.41.4_suppl.TPS658
Abstract #
TPS658
Poster Bd #
P11
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized, parallel arm, phase II study of telotristat (Xermelo) in combination with lutetium Lu 177 dotatate (Lutathera) in well-differentiated neuroendocrine tumors (NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.
First Author: Thorvardur Ragnar Halfdanarson
Poster
2023 ASCO Annual Meeting
LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).
First Author: Rohini Sharma